Elequin Capital’s Halozyme HALO Stock Holding History

Elequin Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.7K	Sell	165 -349	-68%	-$24.6K	﹤0.01%	317
2025 Q4	$34.6K	Buy	+514	New	+$34.6K	﹤0.01%	161
2025 Q1	–	Sell	-402	Closed	-$19.2K	–	457
2024 Q4	$19.2K	Buy	402 +25	+7%	+$1.28K	﹤0.01%	264
2024 Q3	$21.6K	Buy	+377	New	+$21.6K	﹤0.01%	139
2024 Q2	–	Sell	-374	Closed	-$15.2K	–	257
2024 Q1	$15.2K	Buy	+374	New	+$14K	﹤0.01%	65
2023 Q3	–	Sell	-190	Closed	-$6.85K	–	492
2023 Q2	$6.85K	Buy	+190	New	+$6.48K	﹤0.01%	338
2022 Q4	–	Sell	-468	Closed	-$19K	–	665
2022 Q3	$19K	Buy	468 +153	+49%	+$6.76K	0.01%	162
2022 Q2	$14K	Buy	315 +89	+39%	+$3.85K	﹤0.01%	212
2022 Q1	$9K	Buy	+226	New	+$8.05K	﹤0.01%	170

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Elequin Capital's HALO Position: Q1 2026 in Review

Elequin Capital reduced its Halozyme (HALO) stake by 68% in Q1 2026, selling an estimated $24.6K and leaving 165 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Elequin Capital first reported a position in HALO in Q1 2022 and has held it in 9 quarters since. The position peaked at $34.6K in Q4 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

Elequin Capital held 165 shares of Halozyme worth $10.7K as of Q1 2026.
Elequin Capital sold 349 Halozyme shares in Q1 2026, an estimated $24.6K.
Halozyme made up ﹤0.01% of Elequin Capital's portfolio in Q1 2026, its #317 holding.
Elequin Capital first reported a position in Halozyme in Q1 2022 and has held it in 9 quarters since.
Elequin Capital's Halozyme position peaked at $34.6K in Q4 2025.
634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Elequin Capital's 13F filing for Q1 2026, filed 11 May 2026.